Jia Wang

Nanjing, 211166, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

SESN1 is a negative regulator of MAVS and dynamically expressed during RNA viral infection.

SESN1 is a negative regulator of MAVS and dynamically expressed during RNA viral infection.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: August 26, 2026

Tumor targeting dendritic nanocarrier with immunogenic cell death inducing and TIGIT blockade for synergistic chemo-immunotherapy against TNBC.

Tumor targeting dendritic nanocarrier with immunogenic cell death inducing and TIGIT blockade for synergistic chemo-immunotherapy against TNBC.

Journal: Journal of nanobiotechnology

Published: April 27, 2025

Immunomodulating platelet-mimicking nanoparticles for AIE-based enhanced photodynamic immunotherapy against lung cancer.

Immunomodulating platelet-mimicking nanoparticles for AIE-based enhanced photodynamic immunotherapy against lung cancer.

Journal: Materials today. Bio

Published: December 29, 2024

Preclinical Pharmacokinetics and in vitro Metabolism of FHND5071, a Novel Selective RET Kinase Inhibitor.

Preclinical Pharmacokinetics and in vitro Metabolism of FHND5071, a Novel Selective RET Kinase Inhibitor.

Journal: European journal of drug metabolism and pharmacokinetics

Published: June 29, 2023

Synthesis and Evaluation of 2-Amine-4-oxyphosaniline Pyrimidine Derivatives as EGFR L858R/T790M/C797S Mutant Inhibitors.

Synthesis and Evaluation of 2-Amine-4-oxyphosaniline Pyrimidine Derivatives as EGFR L858R/T790M/C797S Mutant Inhibitors.

Journal: Chemical & pharmaceutical bulletin

Published: December 14, 2022

KPT-330 and Y219 exert a synergistic antitumor effect in triple-negative breast cancer through inhibiting NF-κB signaling.

KPT-330 and Y219 exert a synergistic antitumor effect in triple-negative breast cancer through inhibiting NF-κB signaling.

Journal: FEBS open bio

Published: November 26, 2022

Preclinical Pharmacokinetics, Tissue Distribution and in vitro Metabolism of FHND6091, a Novel Oral Proteasome Inhibitor.

Preclinical Pharmacokinetics, Tissue Distribution and in vitro Metabolism of FHND6091, a Novel Oral Proteasome Inhibitor.

Journal: Drug design, development and therapy

Published: April 28, 2022

Targeted regulation of tumor microenvironment through the inhibition of MDSCs by curcumin loaded self-assembled nano-filaments.

Targeted regulation of tumor microenvironment through the inhibition of MDSCs by curcumin loaded self-assembled nano-filaments.

Journal: Materials today. Bio

Published: March 31, 2022

Design, synthesis and docking studies of novel dipeptidyl boronic acid proteasome inhibitors constructed from αα- and αβ-amino acids.

Design, synthesis and docking studies of novel dipeptidyl boronic acid proteasome inhibitors constructed from αα- and αβ-amino acids.

Journal: Bioorganic & medicinal chemistry letters

Published: January 16, 2016

Showing 1-9 of 9

Last Updated: 09/26/2026